Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression DOI

Basma M E Mohamed,

Mohamed E. A. Abdelrahim

World Journal of Clinical Cases, Journal Year: 2024, Volume and Issue: 12(32), P. 6538 - 6542

Published: Sept. 23, 2024

In this editorial, we comment on the article by Lei et al, with a specific focus timing of initiation antifibrotic agent pirfenidone (PFD) in management idiopathic pulmonary fibrosis (IPF) and its impact lung function IPF patients. PFD is an that widely used both early advanced stages. It inhibits various pathways has antifibrotic, anti-inflammatory, antioxidant properties. Despite dosage lowering, slowed progression maintained functional capacity. The 6-min walk distance test indicated patients tolerated adverse events well, significantly reduced incidence episodes death. Even when single disease-progression event occurred, continuing treatment had benefits.

Language: Английский

Decoding the role of extracellular vesicles in pathogenesis of cystic fibrosis DOI Creative Commons

P.S. Kalsi,

Nikhil Gupta, Gitanjali Goyal

et al.

Molecular and Cellular Pediatrics, Journal Year: 2025, Volume and Issue: 12(1)

Published: April 21, 2025

Language: Английский

Citations

0
Timing impact on the initiation of pirfenidone therapy on idiopathic pulmonary fibrosis disease progression DOI

Basma M E Mohamed,

Mohamed E. A. Abdelrahim

World Journal of Clinical Cases, Journal Year: 2024, Volume and Issue: 12(32), P. 6538 - 6542

Published: Sept. 23, 2024

In this editorial, we comment on the article by Lei et al, with a specific focus timing of initiation antifibrotic agent pirfenidone (PFD) in management idiopathic pulmonary fibrosis (IPF) and its impact lung function IPF patients. PFD is an that widely used both early advanced stages. It inhibits various pathways has antifibrotic, anti-inflammatory, antioxidant properties. Despite dosage lowering, slowed progression maintained functional capacity. The 6-min walk distance test indicated patients tolerated adverse events well, significantly reduced incidence episodes death. Even when single disease-progression event occurred, continuing treatment had benefits.

Language: Английский

Citations

1